The DOI matches its Crossref record.
Virus treatment questioned after gene therapy death
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although viral vectors have been widely used in the delivery of the CRISPR/Cas9 system in vitro and in vivo, their fundamental shortcomings, such as the risk of carcinogenesis, limited insertion size, immune responses and difficulty in large-scale production, severely limit their further applications.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [69]
In the citing paper
“Zuris et al. injected Cas9:sgRNA complexes targeting GFP gene into the cochlea of transgenic Atoh1-GFP mice. This system resulted in ~20% Cas9-mediated genome modification in hair cells [69].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [69]
Citations
Cited by
Sorted by citations
Dufès, C., Uchegbu, I. F., & Schätzlein, A. G. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.017 · Cited by 984
“The fact that an adenoviral therapy for direct injection into head and neck cancer has been licensed recently in China [1] is just one indication of this, while highly publicised reports of the risks of some genetic therapies serve as a reminder of some of the potential risks of this emerging therapeutic approach [2,3…”
BackgroundPolyethylenimine-based non-viral gene delivery systems
Lungwitz, U., Breunig, M., Blunk, T., & Göpferich, A. M. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.11.011 · Cited by 998
The role of nitric oxide in cancer
Xu, W., Liu, L.-Z., Loizidou, M., Ahmed, M., & Charles, I. G. (2002) · Cell Research · doi:10.1038/sj.cr.7290133 · Cited by 829
Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes
Wahlgren, J., Karlson, T. D. L., Brisslert, M., Sani, F. V., Telemo, E., Sunnerhagen, P., & Valadi, H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks463 · Cited by 727
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Metadata
- Authors
- Lehrman, S.
- Corresponding author
- Lehrman, Sally
- ORCID
- Lehrman, Sally
- Venue
- Nature
- Published
- 1999-10-07
- Volume
- 401
- Issue
- 6753
- Pages
- 517-518
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1606853210
- Cited by
- 576
- References
- 0
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 11 · 2023: 15 · 2022: 17 · 2021: 12 · 2020: 18 · 2019: 16 · 2018: 18 · 2017: 14 · 2016: 14 · 2015: 24 · 2014: 30 · 2013: 23 · 2012: 31
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Funders
- Brigham and Women's Hospital
- University of East Anglia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- gene therapy, viral vectors, recombinant adeno-associated virus, clinical trial safety
- MeSH terms
- Adenoviridae, Adult, Fever, Genetic Vectors, Humans, Male, Ornithine Carbamoyltransferase, Thrombosis, Genetic Therapy, Clinical Trials, Phase I as Topic, Fatal Outcome, Risk Assessment, Ornithine Carbamoyltransferase Deficiency Disease, Advisory Committees, Government Regulation, Federal Government, Research Subjects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
